OBT076

Phase 1Small molecule

GGroupe Oncologie Radiotherapie Tete et Cou

OBT076 is one of 37 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adenoid Cystic CarcinomaActive, not recruiting

Adenoid Cystic CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Adenoid Cystic Carcinoma

#DrugCompanyPhaseTrials

Afinitor

Adriamycin

Lenvima

4 4

Keytruda

Merck & Co.

Phase 2

2 5

TKI258

Novartis

Phase 2

2 6

Padcev

Pfizer

Phase 2

1 7

Sutent

Pfizer

Phase 2

1 8

Stivarga

Bayer

Phase 2

1 9

Ellence

Pfizer

Phase 2

1 10

Gleevec

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adenoid Cystic Carcinoma1 trial

Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Terminated·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 1·NCT05930951·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OBT076. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OBT076 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OBT076. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Groupe Oncologie Radiotherapie Tete et Cou company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGroupe Oncologie Radiotherapie Tete et Cou

OBT076

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adenoid Cystic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News